Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Clinical Benefit of Allogeneic Melanoma Cell Lysate-Pulsed Autologous Dendritic Cell Vaccine in MAGE-Positive Colorectal Cancer Patients.

Toh HC, Wang WW, Chia WK, Kvistborg P, Sun L, Teo K, Phoon YP, Soe Y, Tan SH, Hee SW, Foo KF, Ong S, Koo WH, Zocca MB, Claesson MH.

Clin Cancer Res. 2009 Dec 15;15(24):7726-7736.

2.

Vaccination with melanoma lysate-pulsed dendritic cells, of patients with advanced colorectal carcinoma: report from a phase I study.

Burgdorf SK, Fischer A, Claesson MH, Kirkin AF, Dzhandzhugazyan KN, Rosenberg J.

J Exp Clin Cancer Res. 2006 Jun;25(2):201-6.

PMID:
16918131
3.

Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma.

Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M, Rieder E, Pfragner R, Brostjan C, Riss S, Niederle B, Gnant M, Stift A.

Oncol Rep. 2009 Jun;21(6):1585-92.

PMID:
19424640
4.

Dendritic cell vaccination of patients with metastatic colorectal cancer.

Burgdorf SK.

Dan Med Bull. 2010 Sep;57(9):B4171.

PMID:
20816019
5.

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.

Salcedo M, Bercovici N, Taylor R, Vereecken P, Massicard S, Duriau D, Vernel-Pauillac F, Boyer A, Baron-Bodo V, Mallard E, Bartholeyns J, Goxe B, Latour N, Leroy S, Prigent D, Martiat P, Sales F, Laporte M, Bruyns C, Romet-Lemonne JL, Abastado JP, Lehmann F, Velu T.

Cancer Immunol Immunother. 2006 Jul;55(7):819-29. Epub 2005 Sep 27.

PMID:
16187085
6.

Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate.

Vilella R, Benítez D, Milà J, Lozano M, Vilana R, Pomes J, Tomas X, Costa J, Vilalta A, Malvehy J, Puig S, Mellado B, Martí R, Castel T.

Cancer Immunol Immunother. 2004 Jul;53(7):651-8. Epub 2004 Mar 16.

PMID:
14999431
7.

[Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].

Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.

Ai Zheng. 2006 May;25(5):625-30. Chinese.

PMID:
16687087
8.

Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression.

Geiger JD, Hutchinson RJ, Hohenkirk LF, McKenna EA, Yanik GA, Levine JE, Chang AE, Braun TM, Mulé JJ.

Cancer Res. 2001 Dec 1;61(23):8513-9.

9.

[Therapeutic efficacy of dendritic cells pulsed by autologous tumor cell lysate in combination with CIK cells on advanced renal cell carcinoma].

Wang H, Feng F, Zhu M, Wang R, Wang X, Wu Y, Zhuang Z.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2015 Jan;31(1):67-71. Chinese.

PMID:
25575061
10.

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

Pandha HS, John RJ, Hutchinson J, James N, Whelan M, Corbishley C, Dalgleish AG.

BJU Int. 2004 Aug;94(3):412-8.

11.

Autologous dendritic cells pulsed with allogeneic tumor cell lysate in mesothelioma: From mouse to human.

Aerts JG, de Goeje PL, Cornelissen R, Kaijen-Lambers MEH, Bezemer K, van der Leest C, Mahaweni NM, Kunert A, Eskens FALM, Waasdorp C, Braakman E, van der Holt B, Vulto AG, Hendriks RW, Hegmans JPJJ, Hoogsteden HC.

Clin Cancer Res. 2017 Dec 12. pii: clincanres.2522.2017. doi: 10.1158/1078-0432.CCR-17-2522. [Epub ahead of print]

PMID:
29233904
12.

A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer.

Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, Geiger JD, Mulé JJ.

Clin Cancer Res. 2002 Apr;8(4):1021-32.

13.

Phase I/II study of immunotherapy using autologous tumor lysate-pulsed dendritic cells in patients with metastatic renal cell carcinoma.

Kim JH, Lee Y, Bae YS, Kim WS, Kim K, Im HY, Kang WK, Park K, Choi HY, Lee HM, Baek SY, Lee H, Doh H, Kim BM, Kim CY, Jeon C, Jung CW.

Clin Immunol. 2007 Dec;125(3):257-67. Epub 2007 Oct 3.

PMID:
17916447
14.

Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients.

Escobar A, López M, Serrano A, Ramirez M, Pérez C, Aguirre A, González R, Alfaro J, Larrondo M, Fodor M, Ferrada C, Salazar-Onfray F.

Clin Exp Immunol. 2005 Dec;142(3):555-68.

15.

Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.

López MN, Pereda C, Segal G, Muñoz L, Aguilera R, González FE, Escobar A, Ginesta A, Reyes D, González R, Mendoza-Naranjo A, Larrondo M, Compán A, Ferrada C, Salazar-Onfray F.

J Clin Oncol. 2009 Feb 20;27(6):945-52. doi: 10.1200/JCO.2008.18.0794. Epub 2009 Jan 12.

PMID:
19139436
16.

Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.

Baek S, Kim CS, Kim SB, Kim YM, Kwon SW, Kim Y, Kim H, Lee H.

J Transl Med. 2011 Oct 20;9:178. doi: 10.1186/1479-5876-9-178.

17.

Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.

Ridolfi L, Petrini M, Fiammenghi L, Granato AM, Ancarani V, Pancisi E, Brolli C, Selva M, Scarpi E, Valmorri L, Nicoletti SV, Guidoboni M, Riccobon A, Ridolfi R.

Melanoma Res. 2011 Dec;21(6):524-9. doi: 10.1097/CMR.0b013e32834b58fa.

PMID:
21909041
18.

Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2.

Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N.

Melanoma Res. 2003 Oct;13(5):521-30.

PMID:
14512794
19.

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

Höltl L, Ramoner R, Zelle-Rieser C, Gander H, Putz T, Papesh C, Nussbaumer W, Falkensammer C, Bartsch G, Thurnher M.

Cancer Immunol Immunother. 2005 Jul;54(7):663-70. Epub 2004 Dec 17.

PMID:
15918076
20.

Long-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma.

Onishi H, Morisaki T, Baba E, Nakamura M, Inaba S, Kuroki H, Matsumoto K, Katano M.

Anticancer Res. 2011 Nov;31(11):3995-4005.

PMID:
22110233

Supplemental Content

Support Center